Dr. Mark Dickson, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Studies Liposarcoma
Studies Sarcoma
4 reported clinical trials
4 drugs studied
Area of expertise
1Liposarcoma
Stage IV
Stage III
2Sarcoma
Stage IV
Stage III
Affiliated Hospitals
More about Mark Dickson, MD
Clinical Trial Related6 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 0 Active Clinical TrialsTreatments Mark Dickson, MD has experience with
- Abemaciclib
- Placebo
- Nelfinavir Mesylate
- TP-1287
Breakdown of trials Mark Dickson, MD has run
Kaposi's Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Dickson, MD specialize in?
Mark Dickson, MD focuses on Liposarcoma and Sarcoma. In particular, much of their work with Liposarcoma has involved Stage IV patients, or patients who are Stage III.
Is Mark Dickson, MD currently recruiting for clinical trials?
No, Mark Dickson, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Mark Dickson, MD has studied deeply?
Yes, Mark Dickson, MD has studied treatments such as Abemaciclib, Placebo, Nelfinavir Mesylate.
What is the best way to schedule an appointment with Mark Dickson, MD?
Apply for one of the trials that Mark Dickson, MD is conducting.
What is the office address of Mark Dickson, MD?
The office of Mark Dickson, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.